CLINICAL AND PHARMACOLOGICAL PECULIARITIES OF CETIRIZINE USE FOR THE THERAPY OF ALLERGIC DISEASES IN CHILDREN
https://doi.org/10.15690/pf.v11i3.1003
Abstract
The review is dedicated to treatment of allergic diseases in children, particularly to the use of the 2nd generation antihistamine. It demonstrates that mediator histamine has the crucial role in pathophysiology of the allergic reaction. Antihistamines block histamine action aimed at H1 receptors by way of competitive inhibition. The 2nd generation antihistamines are the drugs of choice for the treatment of allergic diseases due to the absence of sedative effect. The review presents clinical and pharmacological description of the selective 2nd generation antihistamine cetirizine, efficacy and safety of which have been appraised in numerous long-term clinical studies in children with allergic rhinitis, urticaria and atopic dermatitis.
About the Authors
Yu. G. Levina
Scientific Center of Children’s Health, Moscow
Sechenov First Moscow State Medical University
Russian Federation
MD, head of the department of standardization and clinical pharmacology, assistant professor at the department of allergology and clinical immunology of the pediatric faculty of I.M. Sechenov First Moscow State Medical University
Russian Federation
MD, head of the department of standardization and clinical pharmacology, assistant professor at the department of allergology and clinical immunology of the pediatric faculty of I.M. Sechenov First Moscow State Medical University
L. S. Namazova-Baranova
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Pirogov Russian National Medical Research University, Moscow
Russian Federation
Russian Federation
A. A. Alexeeva
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
E. A. Vishneva
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
K. E. Efendieva
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
A. Y. Tomilova
Scientific Center of Children’s Health, Moscow, Russian Federation
Sechenov First Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
References
1. Namazova-Baranova L. S. Allergiya u detei — ot teorii k praktike [Allergy in Children – from Theory to Practice]. Moscow, 2010. 668 p.
2. Vishneva E. A., Alexeeva A. A., Gevorkyan A. K. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2008; 5 (2): 33–37.
3. Polos'yants O.B., Silina E.G., Namazova L.S. Lechashchii vrach = Practicing doctor. 2001; 3.
4. Namazova-Baranova L. S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2009; 3: 52.
5. Allergologiya i immunologiya. Pod obshchei redaktsiei A.A. Baranova i R.M. Khaitova [Allergology and Immunology. Edited by A.A. Baranov, R.M. Khaitov]. Moscow, 2008–2009. p. 75.
6. Vishneva E. A. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2009; 6 (1): 70–74.
7. Monique P. Curran, Lesley J. Scott, Caroline M. Perry. Cetirizine A. Review of its Use in Allergic Disorders. Drugs. 2004; 64 (5): 523–561.
8. Gushchin I.S. Tsetirizin — etalon N1-antigistaminnogo sredstva (Cetirizine – Reference H1-Antihistamine). Available at: www.health-medix.com. 2009; 5 (61): 60–70.
9. Simons F. E., Johnston L., Simons K. J. Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children. Pediatr. Allergy Immunol. 2000 May; 11 (2): 116–9.
10. Simons F. E., Semus M., Goritz S. S., Simons K. J. H1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr. Allergy Immunol. 2003 Jun; 14 (3): 207–11.
11. Koller M., Hilger R. A., Rihoux J. P. et al. Cetirizine exerts anti-inflammatory effects on human neutrophils. Int. Arch. Allergy Immunol. 1996 May; 110 (1): 52–56.
12. Kondyurina E.G., Elkina T.N., Gribanova O.A. Russkii meditsinskii zhurnal = Russian medical journal. 2013; 2: 63–65.
13. Di Gioacchino M., Verna N., Cavallucci E. et al. Steroid and antihistamines modulate RANTES release in cultured peripheral blood mononuclear cells of atopic patients. Int. J. Immunopathol. Pharmacol. 2002 Jan; 15 (1): 27–34.
14. Dobashi K., Iizuka K., Houjou S. et al. Effect of cetirizine on antigen-induced tracheal contraction of passively sensitized guinea pigs. Ann. Allergy Asthma Immunol. 1996 Oct; 77 (4): 310–318.
15. Pfizer Inc. Zyrtec (cetirizine hydrochloride): tablets and syrup. For oral use [US prescribing information]. New York, Pfizer Inc., 2003.
16. Ferrer M.1., Morais-Almeida M., Guizova M., Khanferyan R. Evaluation of treatment satisfaction in children with allergic disease treated with an antihistamine: an international, non–interventional, retrospective study. Clin. Drug. Investig. 2010; 30 (1): 15–34.
17. Stevenson J., Cornah D., Evrard P. et al. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr. Res. 2002 Aug; 52 (2): 251–257.
18. Simons F. E. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis: ETAC Study Group. Early Treatment of the Atopic Child. J. Allergy Clin. Immunol. 1999 Aug; 104 (2 Pt. 1): 433–440.
19. Winder J. A., Noonan M. J., Lumry W. R. et al. Absence of QT (c) prolongation with cetirizine in children aged 6 to 11 years. Pediatr. Asthma Allergy Immunology. 1996; 10 (4): 181–190.
20. Simons F. E., Silas P., Portnoy J. M. et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double blind, placebocontrolled study. J. Allergy Clin. Immunol. 2003 Jun; 111 (6): 1244–1248.
21. Bousquet J. et al. Allergy. 2008; 63 (Suppl. 86): 8–160.
22. Levin Yu.G. et al. Voprosy sovremennoi pediatrii = Current pediatrics. 2010; 9 (6): 45–51.
23. Allegra L., Paupe J., Wieseman H. G. et al. Cetirizine for seasonal allergic rhinitis in children aged 2–6 years. A double-blind comparison with placebo. Pediatr. Allergy Immunol. 1993; 4 (3): 157–161.
24. Vishneva E. A., Namazova-Baranova L. S., Alexeeva A. A., Efendieva K. E., Levina Yu. G., Voznesenskaya N. I., Tomilova A. Yu., Muradova O. I., Selimzyanova L. R., Promyslova E. A. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2014; 11 (1): 6–14.
25. Pearlman D. S., Lumry W. R., Winder J. A. et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebocontrolled study. Clin. Pediatr. (Phila). 1997 Apr; 36 (4): 209–215.
26. Ratner P., Gillman S., LaForce C. et al. A randomized, double blind, parallel group, placebo controlled, multicenter study of the efficacy and safety of Zyrtec (cetirizine HCL) syrup vs. Claritin (loratadine) syrup vs. placebo in the treatment of children with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2003 Jan; 90 (1): 121–122.
27. Masi M., Candiani R., van de Venne H. A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr. Allergy Immuno. 1993; 4 (Suppl. 4): 47–52.
28. Сiprandi G., Passalacqua G., Mincarini M. et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann. Allergy Asthma Immunol. 1997; 79: 507–511.
29. Lauriello M., Muzi P., Di Rienzo L. et al. A two year course of specific immunotherapy or of continuous antihistamine treatment reverses eosinophilic inflammation in severe persistent allergic rhinitis. Acta Otorhinolaryngol. Ital. 2005; 25: 284–291.
30. Ciprandi G., Tosca M., Ricca V. et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin. Exp. Allergy. 1997; 27: 1160–1166.
31. Ciprandi G., Tosca M. A., Milanese M. et al. Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis. Eur. Ann. Allergy Clin. Immunol. 2004; 36: 237–240.
32. Fasce L., Ciprandi G., Pronzato C. et al. Cetirizine reduces ICAM–I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int. Arch. Allergy Immunol. 1996; 109: 272–276.
33. Gillman S. A., Blatter M., Condemi J. J. et al. The health-related quality of life effects of once-daily cetirizine HCl syrup in children with seasonal allergic rhinitis. Clin. Pediatr. (Phila). 2002 Nov–Dec; 41 (9): 687–696.
34. Lai D. S., Lue K. H., Hsieh J. C. et al. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhini tis. Ann. Allergy Asthma Immunol. 2002 Dec; 89 (6): 589–598.
35. Baelde Y., Dupont P. Cetirizine in children with chronic allergic rhinitis. A multicentre double-blind study of two doses of cetirizine and placebo. Drug. Invest. 1992; 4 (6): 466–472.
36. De Benedictis F. M., Forenza N., Armenio L. et al. Efficacy and safety of cetirizine and oxatomide in young children with perennial allergic rhinitis: a 10 day, multicenter, double-blinded, randomized, parallel-group study. Pediatr. Asthma Allergy Immunol. 1997; 11 (2): 119–128.
37. Jobst S., van den Wijngaart W., Schubert A. et al. Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis. Allergy. 1994 Sep; 49 (8): 598–604.
38. Sienra-Monge J. J., Gazca-Aguilar A., Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am. J. Ther. 1999 May; 6 (3): 149–155.
39. Klein P. A., Clark R. A. F. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch. Dermatol. 1999; 135: 1522–1525.
40. Wahlgren C. F., Hagermark O., Bergstrom R. The antipruritic effect of a sedative and a nonsedative antihistamine in atopic dermatitis. Br. J. Derm. 1990; 122: 545–551.
41. Hannuksela M., Kalimo K., Lammintausta K., Turjanmaa K., Vajionen E., Coulie P. J. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann. Allergy. 1993; 70: 127–133.
42. Namazova-Baranova L. S., Kulichenko T. V., Borovik T. E., Makarova S. G., Novik G. A., Petrovskii F. I., Vishneva E. A., Alexeeva A. A. Atopicheskii dermatit: rukovodstvo dlya vrachei. Bolezni detskogo vozrasta ot A do Ya [Atopic Dermatitis: Guidelines for Physicians. Pediatric Diseases from A to Z]. Moscow, Pediatr, 2014. p. 40.
43. Diepgen T. L. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr. Allergy Immunol. 2002 Aug; 13 (4): 278–286.
44. La Rosa M., Ranno C., Musarra I. et al. Double-blind study of cetirizine in atopic eczema in children. Ann. Allergy. 1994 Aug; 73 (2): 117–122.
45. Simons F. E. Prevention of acute urticaria in young children with atopic dermatitis. J. Allergy Clin. Immunol. 2001 Apr; 107 (4): 703–706.
46. Ciprandi G., Frati F., Marcucci F., Sensi L., Milanese M., Tosca M. A. Long-term cetirizine treatment may reduce new sensitisations in allergic children: a pilot study. Eur Ann Allergy Clin. Immunology. 2003 Jun; 35 (6): 208–211.
Review
For citations:
Levina Yu.G., Namazova-Baranova L.S., Alexeeva A.A., Vishneva E.A., Efendieva K.E., Tomilova A.Y. CLINICAL AND PHARMACOLOGICAL PECULIARITIES OF CETIRIZINE USE FOR THE THERAPY OF ALLERGIC DISEASES IN CHILDREN. Pediatric pharmacology. 2014;11(3):20-26. https://doi.org/10.15690/pf.v11i3.1003
Views:
1212
Email this article 